相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality
Karina Raimundo et al.
JOURNAL OF RHEUMATOLOGY (2019)
Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model
Jingwen Guo et al.
TOXICOLOGY LETTERS (2019)
Impact of Lung Function Decline on Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF)
M. Kreuter et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis Results of the INJOURNEY Trial
Carlo Vancheri et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)
Ulrich Costabel et al.
RESPIRATION (2017)
Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease
Jake G. Natalini et al.
RESPIRATORY MEDICINE (2017)
Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014
Theresa M. Hunter et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Joshua J. Solomon et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research
Eric S. White et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
Dinesh Khanna et al.
JOURNAL OF RHEUMATOLOGY (2016)
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Juergen Behr et al.
LANCET RESPIRATORY MEDICINE (2016)
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)
Takekazu Iwata et al.
RESPIRATORY RESEARCH (2016)
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group
Dinesh Khanna et al.
JOURNAL OF RHEUMATOLOGY (2015)
Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients
Hui Huang et al.
MEDICINE (2015)
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Takashi Ogura et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Katrin Hostettler et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
Marita Cross et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease A Dance Promote Clinical and Translational Research
Tracy J. Doyle et al.
CHEST (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Predictors of mortality in rheumatoid arthritis-related interstitial lung disease
Deborah Assayag et al.
RESPIROLOGY (2014)
Rheumatoid arthritis interstitial lung disease: Time to take notice
Joshua J. Solomon et al.
RESPIROLOGY (2014)
Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
Joshua J. Solomon et al.
RESPIRATORY MEDICINE (2013)
Rheumatoid Arthritis-Interstitial Lung Disease-associated Mortality
Amy L. Olson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Novel therapeutic approaches for pulmonary fibrosis
Arnab Datta et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Antifibrotic activities of pirfenidone in animal models
C. J. Schaefer et al.
EUROPEAN RESPIRATORY REVIEW (2011)
Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis
Tim Bongartz et al.
ARTHRITIS AND RHEUMATISM (2010)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
Societal cost of rheumatoid arthritis patients in the US
Howard Birnbaum et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
C. J. Zappala et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
E. J. Kim et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Pirfenidone in idiopathic pulmonary fibrosis
H. Taniguchi et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Rheumatoid Arthritis-Associated Interstitial Lung Disease The Relevance of Histopathologic and Radiographic Pattern
Eunice J. Kim et al.
CHEST (2009)
Progressive preclinical interstitial lung disease in rheumatoid arthritis
Bernadette R. Gochuico et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Prognosis of fibrotic interstitial pneumonia - Idiopathic versus collagen vascular disease-related subtypes
Joo Hun Park et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Idiopathic pulmonary fibrosis - Prognostic value of changes in physiology and six-minute-walk test
Kevin R. Flaherty et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Histopathologic pattern and clinical features of rheumatoid arthritis associated interstitial lung disease
HK Lee et al.
CHEST (2005)
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
A Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis
HR Collard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis
S Nagai et al.
INTERNAL MEDICINE (2002)
Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome
WA Gahl et al.
MOLECULAR GENETICS AND METABOLISM (2002)
分享论文
